 |
Turna Ray is the editor of GenomeWeb's Pharmacogenomics Reporter. She covers pharmacogenomics, personalized medicine, and companion diagnostics. E-mail Turna Ray or follow her GenomeWeb Twitter account at @PGxReporter. |
Study Suggests Two-Gene Combo Predicts Spectrum of Response to ARCA's Beta Blocker Gencaro
October 24, 2012
Study Suggests Two-Gene Combo Predicts Spectrum of Response to ARCA's Beta Blocker Gencaro
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- ARCA's Bucindolol Clinical Trial Plan Gets FDA Green Light; Firm Evaluates Funding Options
May 19, 2010 / Pharmacogenomics Reporter - ARCA Awarded Method Patent for Gene Response Testing with Investigational Heart Failure Drug
March 31, 2010 / Pharmacogenomics Reporter - Correlogic Developing 'Second Generation' OvaCheck; Seeks Ruling on Quest, LabCorp Licenses
July 8, 2011 / ProteoMonitor - When Might Warfarin PGx Be Better Than Pradaxa? Stakeholders Weigh In
October 27, 2010 / Pharmacogenomics Reporter - New Data on CYP2C19 Loss-of-Function Alleles Questions Impact of Plavix PGx Testing
September 1, 2010 / Pharmacogenomics Reporter